Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
-
Catheter Cardiovasc Interv · Oct 2004
Randomized Controlled Trial Comparative Study Clinical TrialPatient tolerance and resource utilization associated with an arterial closure versus an external compression device after percutaneous coronary intervention.
We assessed patient tolerance and resource utilization of using the AngioSeal closure device versus assisted manual compression using the Femostop device after percutaneous coronary intervention (PCI). Patients undergoing PCI with clean arterial access and no procedural hematoma were randomized to receive the AngioSeal or Femostop device to achieve femoral arterial hemostasis. Times from procedure end to removal from angiography table, hemostasis, ambulation, and hospital discharge were recorded. ⋯ There were no differences in ultrasound-determined vascular complications (two each). Femoral access site closure using the AngioSeal device resulted in a small delay in leaving the angiography suite and a higher disposable cost compared to using the Femostop device. However, patients receiving the AngioSeal were able to ambulate sooner and reported less pain, which may justify the increased costs involved.
-
Catheter Cardiovasc Interv · Sep 2004
Case ReportsEndovascular repair of carotid artery aneurysm with Jostent covered stent: initial experience and one-year result.
Treatment for symptomatic extracranial carotid artery aneurysm is evolving and we describe two cases of successful endovascular treatment of distal internal carotid aneurysm using Jostent, a balloon-expandable coronary polytetrafluoroethylene-covered stent. Both patients remained symptom-free at 1 year after the procedure and patency of the stents was maintained. We conclude that endovascular treatment of carotid artery aneurysm with Jostent is feasible and safe and may be more preferable than conventional strategies.
-
Catheter Cardiovasc Interv · Sep 2004
Percutaneous stent-mounted valve for treatment of aortic or pulmonary valve disease.
The objective of this study was to develop a prosthetic cardiac valve designed for percutaneous transcatheter implantation. Percutaneous catheter-based therapies play a limited role in the management of cardiac valve disease. Surgical implantation of prosthetic valves usually requires thoracotomy and cardiopulmonary bypass. ⋯ Stent-valve implantation proved feasible and compatible with survival in an animal model. Transcatheter implantation of prosthetic valves is possible. Further evolution of this technology will involve lower-profile devices with design features that facilitate vascular delivery, visualization, positioning, deployment, and valvular function.
-
Catheter Cardiovasc Interv · Aug 2004
Multicenter StudyTranscatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: acute results from the FORECAST registry.
Patients with patent foramen ovale (PFO) and paradoxical embolism are at increased risk for recurrent events. Percutaneous PFO closure is a new treatment modality aimed at secondary prevention. We report the multicenter experience of interventional closure of PFO using two different devices in 272 patients. ⋯ The mean procedure time was less than 44 min under either conscious sedation, local or general anesthesia. This is the largest report to date demonstrating the procedural safety, reliability, and feasibility of the transcatheter PFO closure technique with the STARFlex and CardioSEAL septal implants. Randomized clinical trials are currently in progress to identify patients most likely to benefit from this intervention.